^
Association details:
| Biomarker: | IL4 elevation |
|---|---|
| Cancer: | Multiple Myeloma |
| Drug: | bortezomib (Proteasome inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Pretreatment Serum Levels of IL-1 Receptor Antagonist and IL-4 Are Predictors of Overall Survival in Multiple Myeloma Patients Treated with Bortezomib
Published date:
12/26/2021
Excerpt:
However, among the MM patients treated with bortezomib, only IL-4 predicted longer OS in both the univariate and multivariate models: patients with higher level of IL-4 had longer OS...In conclusion, serum pretreatment levels of IL-13 and IL-4 are predictors of better PFS and OS.
DOI:
10.3390/jcm11010112